Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Inflammasome Therapeutics’ Kamuvudine K8 Reduces Geographic Atrophy Lesion Growth by 54% in Phase 2 Study
Phase 2 data for kamuvudine K8, an investigational inflammasome-directed treatment from Inflammasome Therapeutics, were presented during Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting. The 0.7 mg dose was associated with a 54% reduction in…
GenSight Biologics Publishes GS030 PIONEER Optogenetic Therapy Results in the New England Journal of Medicine
GenSight Biologics and the Quinze-Vingts National Ophthalmology Hospital in Paris announced on 8 October 2026 the publication of results from the Phase 1/2 PIONEER trial of GS030 in the New England Journal of Medicine (NEJM). The study evaluated the safety…
Atsena Therapeutics Reports Preliminary LIGHTHOUSE Results for ATSN-201 Gene Therapy in X-Linked Retinoschisis
Atsena Therapeutics reported preliminary findings on 7 October 2026 from Parts A and B of the LIGHTHOUSE trial of ATSN-201, an investigational gene therapy for X-linked retinoschisis (XLRS). The company reported improvements in retinal structure and selected functional measures, including…
2026 Nobel Prize in Medicine Awarded to Optogenetics Pioneers Deisseroth, Hegemann and Nagel
The 2026 Nobel Prize in Physiology or Medicine has been awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel for their foundational work in optogenetics. Announced on 5 October 2026, the award recognizes research that established the ability to control…
Eyestem Research Presents Eyecyte-RPE Cell Therapy Data in Geographic Atrophy at EURETINA 2026
Eyestem Research presented clinical data for Eyecyte-RPE, an investigational retinal pigment epithelium (RPE) cell therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD), at EURETINA 2026 in Vienna. A mean best-corrected visual acuity (BCVA) gain of about…
Sight Sciences Introduces OMNI Ultra Surgical System at AAO 2026
Sight Sciences announced on October 1, 2026 that it would debut its OMNI Ultra Surgical System, the latest version of its implant-free minimally invasive glaucoma surgery (MIGS) platform, at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting in New…
SpyGlass Pharma Acquires Advanced Vision Science to Advance Drug-Eluting IOL Technology for Glaucoma
SpyGlass Pharma announced on October 1, 2026 that it has acquired Advanced Vision Science (AVS), its existing intraocular lens (IOL) manufacturer, for about $13 million. The deal gives SpyGlass direct control over a key component of its investigational BIM-IOL system,…
Kodiak Sciences’ Tarcocimab Meets Noninferiority Endpoint Versus Aflibercept in Phase 3 DAYBREAK Trial in Wet AMD
Kodiak Sciences announced on 28 September 2026 that Zenkuda (tarcocimab tedromer), an investigational anti-vascular endothelial growth factor (VEGF) therapy, met the primary endpoint of its pivotal Phase 3 DAYBREAK trial in neovascular age-related macular degeneration (wet AMD): noninferiority to aflibercept…
MacTel Decoded: Rethinking Conventional Approaches with Novel Neuroprotective Strategies | Ophthalmology Times
Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Charles C. Wykoff, MD, PhD, FASRS; Jed H. Assam, MD, MS; Diana V. Do, MD; and Dante Pieramici, MD,…
When Mites Meet Their Match: Empowering Patients With Targeted Treatment for Demodex Blepharitis | Ophthalmology Times
Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, expert Mile Brujic, OD, FAAO, discusses the burden, diagnosis, and management of Demodex blepharitis, highlighting a recently approved targeted treatment…